<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162159</url>
  </required_header>
  <id_info>
    <org_study_id>CE-CIC-GREN-09-19</org_study_id>
    <nct_id>NCT03162159</nct_id>
  </id_info>
  <brief_title>Adult Height Prediction in Congenital Adrenal Hyperplasia</brief_title>
  <acronym>OPALE Model</acronym>
  <official_title>An Adult Height Prediction Model for Congenital Adrenal Hyperplasia From a National Cohort (OPALE Model Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital Adrenal Hyperplasia (CAH) is a genetic rare disease, which alters the adrenal&#xD;
      production of gluco and mineralo cortico√Øds. The treatment consists in supplementing children&#xD;
      with hydrocortisone. Despite care for these children has improved substantially across&#xD;
      decades, short adult height (AH) still remains an important consequence of the disease. About&#xD;
      20% of patients have an AH below 2 standard deviations compared to their expected AH.&#xD;
&#xD;
      In the OPALE-Model study, the investigators want to collect data from a cohort of 496 CAH&#xD;
      French patients, born between 1970 and 1991 with a known genotype. Using their age, sex,&#xD;
      growth, disease, bone maturation and pubertal data, the investigators will build a model&#xD;
      which allows to predict their AH using data available at 8 years of age. The growth charts&#xD;
      built from this cohort have shown that currently used formula to calculate the predicted AH&#xD;
      (Bayley-Pineau's formula) is not applicable to children with CAH.&#xD;
&#xD;
      In this project, the investigators plan to compute an AH prediction model using data from&#xD;
      children born between 1970 and 1993, and to validate the model using data from a different&#xD;
      cohort (i.e. children born between 1994 and 1998). this choice was due to availability of&#xD;
      data for computing the model first, and in a second stage, data from more recently born&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adult height (AH)</measure>
    <time_frame>up to 18 years</time_frame>
    <description>AH is defined as i) the height recorded after age 20 in boys or 18 in girls; ii) Or the height recorded when bone age is &gt;= 18 years in boys and 16 years in girls; Or iii) the height measured after growth velocity dropped to &lt;= 1 cm/year.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">496</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>cohort for model computing</arm_group_label>
    <description>patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort for model validation</arm_group_label>
    <description>patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of growth and bone maturation data</intervention_name>
    <arm_group_label>cohort for model computing</arm_group_label>
    <arm_group_label>cohort for model validation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adullts with Congenital Adrenal Hyperplasia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children with CAH, genetically proven, classical form, virilizing form, with deficit&#xD;
             of 21 hydroxylase, 11 beta hydroxylase, or 3 beta ol dehydrogenase, born between&#xD;
             1972-1993 (cohort 1) and 1994-1998 (cohort 2).&#xD;
&#xD;
          -  medical charts should be available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic growth altering disease, Turner syndrome, or other genetic&#xD;
             anomaly&#xD;
&#xD;
          -  Patients having received any treatment with Growth Hormone (GH)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Cornu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bretones P, Riche B, Pichot E, David M, Roy P, Tardy V, Kassai B, Gaillard S, Bernoux D, Morel Y, Chatelain P, Nicolino M, Cornu C; French Collaborative CAH Growth Study Group. Growth curves for congenital adrenal hyperplasia from a national retrospective cohort. J Pediatr Endocrinol Metab. 2016 Dec 1;29(12):1379-1388. doi: 10.1515/jpem-2016-0156.</citation>
    <PMID>27852974</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

